These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 5026378)

  • 21. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
    Gattringer B; Steinhäusl H
    Wien Med Wochenschr; 1972 Jun; 122(25):369-71. PubMed ID: 4558132
    [No Abstract]   [Full Text] [Related]  

  • 22. [Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor].
    Streifler M; Vardi J; Kesten M
    Harefuah; 1972 Nov; 83(9):362-4. PubMed ID: 4669737
    [No Abstract]   [Full Text] [Related]  

  • 23. The action of L(-)-dopa on baroreflexes in Parkinsonism.
    Reid JL; Calne DB; George CF; Vakil SD
    Clin Sci; 1972 Dec; 43(6):851-9. PubMed ID: 4646277
    [No Abstract]   [Full Text] [Related]  

  • 24. Methyldopahydrazine as an adjunct to L-dopa therapy in parkinsonism.
    Chase TN; Watanabe AM
    Neurology; 1972 Apr; 22(4):384-92. PubMed ID: 5062828
    [No Abstract]   [Full Text] [Related]  

  • 25. Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism.
    Chase TN
    Neurology; 1970 Dec; 20(12):Suppl:36-40. PubMed ID: 5312403
    [No Abstract]   [Full Text] [Related]  

  • 26. Recent advances in the treatment of Parkinsonism with drugs.
    Rinne UK
    Acta Neurol Scand Suppl; 1972; 51():59-103. PubMed ID: 4576076
    [No Abstract]   [Full Text] [Related]  

  • 27. [Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor].
    Christiani K; Möller WD
    Munch Med Wochenschr; 1973 Apr; 115(16):711-3. PubMed ID: 4197759
    [No Abstract]   [Full Text] [Related]  

  • 28. 3-O-Methyldopa, L-dopa, and trihexyphenidyl in the treatment of Parkinson's disease.
    Muenter MD; Dinapoli RP; Sharpless NS; Tyce GM
    Mayo Clin Proc; 1973 Mar; 48(3):173-83. PubMed ID: 4570387
    [No Abstract]   [Full Text] [Related]  

  • 29. Methyldopa as an adjunct to levodopa treatment of Parkinson's disease.
    Sweet RD; Lee JE; McDowell FH
    Clin Pharmacol Ther; 1972; 13(1):23-7. PubMed ID: 5008190
    [No Abstract]   [Full Text] [Related]  

  • 30. Methyldopa or methyldopahydrazine as levodopa synergists.
    Fermaglich J; Chase TN
    Lancet; 1973 Jun; 1(7814):1261-2. PubMed ID: 4122619
    [No Abstract]   [Full Text] [Related]  

  • 31. Plasma testosterone content of male patients with Parkinson's disease during L-dopa treatment with or without dopadecarboxylase inhibitor.
    Pekkarinen A; Rinne UK; Salokangas R; Siirtola T; Sonninen V
    Acta Neurol Scand Suppl; 1972; 51():129-30. PubMed ID: 4514339
    [No Abstract]   [Full Text] [Related]  

  • 32. Morphological and biochemical studies on liver biopsies of parkinsonian patients treated with levodopa and decarboxylase inhibitor.
    Nevalainen T; Riekkinen P; Rinne UK; Sonninen V
    Acta Neurol Scand; 1974; 50(1):122-30. PubMed ID: 4365556
    [No Abstract]   [Full Text] [Related]  

  • 33. Inhibition of drug metabolism by levodopa in combination with a dopa-decarboxylase inhibitor.
    Vesell ES; Ng L; Passananti GT; Chase TN
    Lancet; 1971 Aug; 2(7720):370. PubMed ID: 4105063
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase.
    Marsden CD; Barry PE; Parkes JD; Zilkha KJ
    J Neurol Neurosurg Psychiatry; 1973 Feb; 36(1):10-4. PubMed ID: 4691682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of Parkinson's disease with L-dopa alone or combined with Ro 4-4602].
    Barbeau A; Gillo-Joffroy L; Mars H; Arsenault A
    Rev Can Biol; 1972; 31():Suppl:169-74. PubMed ID: 5052323
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of Parkinson's disease with levodopa and Ro 4-4602.
    Barbeau A; Gillo-Joffroy L; Mars H
    Clin Pharmacol Ther; 1971; 12(2):353-9. PubMed ID: 4930866
    [No Abstract]   [Full Text] [Related]  

  • 37. Levodopa and Ro 4-4602 in psoriasis.
    Giroux JM; Dubuc R; Barbeau A
    Lancet; 1972 Aug; 2(7772):333-4. PubMed ID: 4115065
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of Parkinson's disease with L-DOPA and an association L-DOPA plus a DOPA decarboxylase inhibitor.
    Fazio C; Agnoli A; Casacchia M; Reitano M; Ruggieri S; Barba C; Volante F
    Z Neurol; 1972; 202(4):347-55. PubMed ID: 4117654
    [No Abstract]   [Full Text] [Related]  

  • 39. [Experiences in the treatment of Parkinsonism using a combination of L-dopa and alpha-methyldopa-hydrazine].
    Vymazal J; Roth B; Nevsímal O
    Cesk Neurol Neurochir; 1976 Mar; 39(2):59-62. PubMed ID: 1260921
    [No Abstract]   [Full Text] [Related]  

  • 40. MK 486 and levodopa in treatment of Parkinsonism.
    Lieberman AN; Derby BM; Feigenson J; Goodgold A; Nesbitte J; Resurreccion EC; Valdivia F
    Dis Nerv Syst; 1973; 34(4):167-71. PubMed ID: 4711885
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.